10 results
10-K
2023 FY
SLRN
Acelyrin Inc
28 Mar 24
Annual report
4:21pm
of a registrational package is subject to regulatory agency review. To the extent we are unable to successfully identify and manage the performance of third-party … package for HS. However, we now would need to conduct and successfully complete both our ongoing Phase 3 trial in HS, as well as an additional Phase 3 trial
8-K
EX-99.1
SLRN
Acelyrin Inc
11 Mar 24
ACELYRIN, INC. Announces Positive Top-line Results from Its Global Phase 2b/3 Clinical Trial of Izokibep in Psoriatic Arthritis
8:05am
; ACELYRIN’s ability to include the ongoing Phase 2b/3 trial in psoriatic arthritis in any registrational package for such indication, which is subject
424B4
SLRN
Acelyrin Inc
5 May 23
Prospectus supplement with pricing info
4:22pm
inclusion into registrational package for HS and non-infectious uveitis (as applicable) if granted orphan drug designation and following consultation … suppurativa (HS) and uveitis. Planned inclusion into registrational package for HS and non-infectious uveitis (as applicable) if granted orphan drug
S-1/A
gannt6ow msawq
1 May 23
IPO registration (amended)
6:10am
S-1
02yow2huw2b
13 Apr 23
IPO registration
5:10pm
S-1
EX-10.13
yb0exm y15t2nj4
13 Apr 23
IPO registration
5:10pm
S-1
EX-10.12
mwzgb2
13 Apr 23
IPO registration
5:10pm
- Prev
- 1
- Next